![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2020
Kurreck, A.; Geissler, M.; Martens, U. M.; Riera-Knorrenschild, J.; Greeve, J.; Florschütz, A.; Wessendorf, S.; Ettrich, T.; Kanzler, S.; Nörenberg, D.; Seidensticker, M.; Held, S.; Buechner-Steudel, P.; Atzpodien, J.; Heinemann, V.; Stintzing, S.; Seufferlein, T.; Tannapfel, A.; Reinacher-Schick, A. C. und Modest, D. P.
(2020):
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).
In: Journal of Cancer Research and Clinical Oncology, Bd. 146, Nr. 10: S. 2681-2691
2017
Geissler, M.; Martens, U. M.; Knorrenschield, R.; Greeve, J.; Florschütz, A.; Tannapfel, A.; Wessendorf, S.; Seufferlein, T.; Kanzler, S.; Heinemann, V.; Held, S. und Reinacher-Schick, A.
(2017):
mFOLFOXIRI plus panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer m(CRC): A randomized phase II VOLFI trial of the AIO (AIO-KRK0109).
In: Annals of Oncology, Bd. 28